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Abstract
Like so many autoimmune diseases, the exact cause of systemic lupus erythematosus (SLE)
remains unknown. Evidence points to both genetics and environment playing roles in the onset
of the disease, but neither acts independent of the other. Genetics are the easier of the two to
study with recent advances in the field making it easier to isolate genes shared by individuals
with the disease. However, genetic studies reveal that there is almost certainly an environmental
component to the development of SLE. The underlying pathology and existing research on
environmental contributors to the development of SLE suggest that viruses could potentially be
an environmental factor that leads to the onset of SLE. Research has been done in the past in an
attempt to establish a connection between viruses and the onset of SLE; however, these studies
have been limited to providing circumstantial evidence due to the limits of existing technologies.
A recent technology called VirScan developed by researchers at Harvard holds the potential to
overcome the limitations of past research. The purpose of this thesis is to present an experimental
approach to use VirScan to determine which viruses leading to the development of lupus.
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Introduction
For the average person, the fatigue and achiness associated with a bad flu is the only
experience that can quantify a day in the life of someone living with SLE.1 Except that chronic,
widespread pain and tiredness is experienced every day.1 For people living with SLE, something
as simple as getting out of bed becomes a difficult and painful task.1 What’s worse is there is no
cure, only symptom management that makes the pain bearable.2 Like a thief, SLE comes and
steals some of the basic pleasures of life that can so easily be taken for granted like being able go
through the day not feeling tired all the time or being able to perform everyday tasks without
pain. Where the thief comes from is unknown and how to keep it from stealing from its victims
has proven difficult to prevent. Most people are unaware of the battle that people with lupus face
on a daily basis and these people often go unnoticed.1 SLE takes something different from each
person, with people often experiencing a broad array of symptoms with numerous combinations
of these symptoms.2
SLE is a difficult disease to quantify because the symptoms vary so greatly between
individuals.2 Tiredness and chronic widespread pain are only a couple of the many different
symptoms that people with SLE experience.2 SLE often goes undiagnosed and is not a disease
that is reportable so estimates of the number of people who have SLE are difficult to obtain.3 The
Lupus Foundation of America has attempted to compile several statistics to help quantify the
existing prevalence and impact of the four forms of lupus, among which SLE is the most
prevalent.4 They estimate that as many as 1.5 million Americans live with lupus, and at least 5
million people worldwide, have one of the four forms of lupus.4 The demographic most heavily
affected by lupus are women of childbearing age, with 9 out of 10 people with lupus being
women between the ages of 15 and 44.4 Research has also shown that there is a significant
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financial impact on individuals living with lupus.5 On average, the cost of medical care directly
related to the treatment of lupus is $33,223 a year, and the financial losses associated with
limitations to productivity caused by lupus range from $1,252 and $20,046 annually.5 This can
add up to a total cost of $50,000 a year in expenses related to lupus. Studies have also shown that
the severity of lupus is worse and mortality rates are higher among minority groups.6 Women of
color are 2 to 3 times more likely to develop lupus compared to Caucasian women.7 Among the
few positives associated with the disease is a low mortality rate with only about 10-15% of
people with lupus suffering from a premature death.7
Like so many other autoimmune diseases, treatment for SLE is mainly focused on
managing symptoms and the cause of the disease is unknown.8 Evidence points to the cause of
SLE being multifaceted, but there is almost certainly a genetic and an environmental component
to the development of lupus.8 The environmental component offers a potential target for the
prevention of SLE, and the investigation of this avenue will be the focus of this thesis.
Investigating an environmental cause of SLE requires a thorough examination of the disease
pathology and pathogenesis. In conjunction with this, the potential mechanisms of interaction
between the environmental agent must be well understood and possess a certain level of
feasibility that makes further investigation justifiable. Finally, it must then be possible to
investigate this connection with a technology that can prove the connection between the
environmental factor and the development of SLE. For the purpose of this thesis, each of these
elements will be investigated in detail and the environmental factor in question will be viruses.
All of these components will provide a wholistic picture of the available data that seeks to
answer the question, “Can viruses cause SLE?” If so, “Can the viruses causing SLE be stopped,
leading to the prevention of SLE?”

3
Methodology
The methodology used to construct this thesis was an extended review of available
literature pertaining to the relationship between viruses and the development of lupus,
specifically systemic lupus erythematosus (SLE). To collect data pertaining to this topic,
databases such as PubMed, PMC, and SciFinder were used to collect relevant and recent data on
the topics investigated. The primary sources used in this paper were articles published in major
scientific journals such as Nature, Science, and Frontiers in Immunology. The topics investigated
include SLE, viruses and autoimmunity, and VirScan. Each of these topics were broken down
into their key components and explained in detail for the purpose of synthesizing a thesis that
illustrates the connection between viruses and SLE, and also introduces a technology that could
be used to then investigate the connection between the two.
By first investigating the disease pathology and pathogenesis of SLE, the groundwork is
laid to show how the pathogenesis could correlate with a viral infection. Then, by further
investigating possible mechanisms, the theory is given feasibility as well as credibility for being
a potential causative agent of SLE. Finally, by introducing a technology that could be employed
to test this theory, this thesis completes the case for future investigation of this connection that
has been thoroughly supported by existing literature throughout the course of this paper. To
justify extensively researching a viral cause for lupus, there must be compelling evidence that
supports this hypothesis. The methodology of this thesis seeks to present the evidence necessary
to justify future research with an extended review of available literature on relevant topics.

4
Systemic Lupus Erythematosus

Overview of Disease
Systemic Lupus Erythematosus (SLE) is the disease most commonly associated with the
term lupus, however it is one among four similar disease processes: neonatal and pediatric lupus
erythematosus (NLE), discoid lupus erythematosus (DLE), drug-induced lupus (DIL), and
systemic lupus erythematosus (SLE).2 It is the most common and widely studied of the four
types of lupus, which is why the term lupus is often used to refer to SLE.2 The word “lupus”
means wolf in Latin and became associated with SLE due to early descriptions of the disease
dating back to the Middle Ages.9 One of the common clinical manifestations of the disease is a
malar rash that can have an appearance similar to that of a wolf bite, which is where the disease
derives its association with the Latin word for wolf.9 The clinical title, systemic lupus
erythematosus, acquires most of its name from the disease manifestations relating to the skin.2
The word erythematosus comes from the Greek word for redness, “erythros”, referring to the
redness observed on the skin and lupus as stated previously also relates to the skin; however, it is
the word systemic that perhaps is the most accurate in describing the nature of this disease.2 SLE
affects almost every organ system in the body, among which it most commonly affects the skin,
joints, and kidneys.2
As a consequence of the many ways SLE can affect the
body, for someone to receive a diagnosis for SLE they must meet at
least four of the eleven criteria based on the most common
symptoms.10 Three of the eleven symptoms used to identify SLE are
related to the skin.10 The first of which is a malar rash (Figure 1),
also called the “butterfly rash” due to its location on the bridge of

Figure 1. Malar rash.11
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the nose and the cheeks.10,11 The second manifestation of
SLE on the skin is a discoid rash (Figure 2) which is a
more severe type of rash that can lead to scarring, and the
final criteria related to the skin is a general sensitivity to
sun exposure.10,12 Lupus can also manifest within the
Figure 2. Discoid rash.12

body as ulcers on the mucosa of the nose and mouth

(Figure 3), and as inflammation of the serosal
membranes.10,13 The sixth criteria for
diagnosing SLE is inflammation of the joints,
which is among the most common symptoms
of SLE; however, like any of the eleven
criteria it is not specific enough to diagnose
SLE by itself.10 Another criteria that is among

Figure 3. Ulcers on the oral mucosa.13

the most common complications of SLE is renal disorders such as abnormal urine protein and
diffuse proliferative glomerulonephritis.10 Conversely, a more rare complication is the
development neurological disorders such as seizures and psychosis.10 The ninth criteria for SLE
diagnosis is a number of hematologic disorders such as anemia, thrombocytopenia and
leukopenia.10 Finally, the last two criteria for the diagnosis of SLE involve the presences of
autoantibodies, which are among the most definitive indicators of SLE.10 Autoantibodies point to
the reason why SLE is classified as an autoimmune disease.10 The specific criteria for diagnosing
lupus differentiate antinuclear antibodies as a separate criterion from the final criteria, which is
any other autoantibodies such as anti-smith, anti-dsDNA and anti-phospholipid antibodies.10
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None of these eleven criteria are enough to diagnose lupus by themselves since each one
of these criteria can be implicated in other disease processes.10 However, when four or more of
these symptoms are present, they are an indicator of a greater underlying problem.14 Every
person who deals with SLE experiences a different array of symptoms with a great deal of
variety in the number of symptoms as well as the severity of these symptoms.14 Most people
experience periods of flare-ups where the symptoms become worse, and it is these flare-ups that
most drug treatments are designed to help prevent or reduce.14 Each element of SLE points back
to the greater underlying issue of the immune system’s failure to function properly.15 An
autoimmune disease is characterized by one’s own immune system attacking self.16
Autoantibodies, one of the most specific indicators of SLE, are evidence of the body’s attempts
to attack self instead of foreign pathogens. There are several different elements besides
autoantibodies that culminate in the disease process of SLE such as apoptosis, inflammation,
genetic factors and environmental factors.16 Each one of these elements adds to the complexity
and diversity of this disease, but each points back immune system’s inability to recognize self
and the aberrant responses that eventually lead to the destruction of self.

Antibodies & Autoantibodies
Preceding an understanding of why the body attacks itself in autoimmune diseases such
as SLE, is foundational knowledge of how the body normally attacks foreign pathogens. Among
the ways that immune system attacks foreign pathogens is the generation of highly variable
proteins called immunoglobulins (Ig) or more commonly, antibodies.17 These types of antibodies
are shaped like the letter “Y” and have two identical regions on each side that have very specific
binding capabilities (Figure 4).17 These regions on the antibody called the paratopes bind to a
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Figure 4. Two-dimensional model of an IgG molecule.17
corresponding region called the epitope on an antigen.17 An antigen is the specific target that an
antibody binds to and can be a number of different things including bacteria, viruses, cells,
proteins, and foreign particles.17 Normally, the body produces antibodies that are specific to
foreign invaders such as viruses and bacteria, but it is also possible for the body to produce
antibodies that are specific to molecules that are normally found in the body.17
Antibodies are produced by cells in the immune system called B lymphocytes or B
cells.17 There are five isotypes of immunoglobulins (IgM, IgG, IgA, IgE and IgD) (Figure 5), and
each possesses a set of functions and targets.17 The preliminary form in which antibodies are
presented is as IgM molecules, which exist as a monomers on the surface of B cells or as a
pentamers in serum.17 The role of IgM is to be less specific and serve as a first line of attack
against new antigens.18 On the surface of B cells, IgM serves as a screener for immature B cells
that have yet to differentiate.18 Different immature B cells present specific IgM monomers on
their surface with low affinity and high reactivity for the purpose of identifying new targets and
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Figure 5. Two-dimensional models of immunoglobulin sturctures.17
activating a more specific response.18 IgM antibodies are also secreted in serum as pentamers to
act as an opsonins.18 An opsonin is a type of biochemical marker that labels antigens for
destruction by phagocytes and also serves as an adhesive that makes antigens, such as bacteria,
easier to phagocytize.18 IgM is not the only class of antibody that can act as an opsonin, and in
their role as an opsonin, antibodies serve as activators for the complement system, which will be
described in more detail later.17 The most common type of immunoglobulin, IgG, mainly serves
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as an opsonin.19 This isotype is secreted by differentiated B cells called plasma cells, and acts as
the central component to the immune system’s ability to respond effectively to antigens to which
it has been previously exposed.19 Aside from floating in serum acting as an opsonin and
activating the complement system, IgG molecules bind to FcγR receptors on T-cells which
activates the response of T-cells.19 IgG executes the most common function associated with
antibodies, however the other three classes of antibodies, while less abundant, serve specific and
vital roles in normal immune function.17 IgA molecules are found in the mucosal linings and
serve to activate the response of mucosal tissues to foreign invaders.17 The presence of IgA
antibodies stimulates mucus production, promotes inflammatory response via the complement
system and acts as an opsonin on antigens present on the surface of the mucosal lining.17 IgE
immunoglobulins specialize in activating granulocytes such as mast cells, basophils, Langerhans
cells and eosinophils.17 These cells possess FcεRI receptors which have an extremely high
affinity for IgE molecules and activate the immune response generally associated with allergies,
which is designed to target larger pathogens such as parasitic worms.17 The last isotype, IgD has
the smallest and least understood role, which is believed to be involved in B cell maturation and
serves as a B cell receptor (BCR) alongside IgM.17
Normally, antibodies do not have a high affinity for molecules regularly found in the
body, but in people with SLE there is a high prevalence of these kinds of antibodies.15 These
self-reacting antibodies are called autoantibodies.15 In healthy individuals, these autoantibodies
or natural antibodies are present in low amounts as mainly IgM molecules.15 It is believed that
these self-reacting IgM antibodies play a maintenance role in healthy individuals and have the
capacity to become harmful when perpetuated.15 The autoantibodies become dangerous when
they class switch from IgM to IgG molecules.15 As IgM molecules, autoantibodies react more
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broadly and are less adhesive, but if mutations occur and the autoantibodies switch classes to
IgG, they become more specific and widespread.15 Normally, the body has mechanisms in place
to prevent this process from taking place, by selecting for B cells that are not self-reactive
through a series of checkpoints.20 If this process is not effective in eliminating self-reactive B
cells, the widespread production of IgG autoantibodies is what eventually leads to the pathogenic
role of autoantibodies.15
There are a number of self-antigens that can be the target of autoantibodies, with some
being more common than others and the specificity of the autoantibodies potentially offering
clues to how SLE will affect the body.20 One classification of autoantibodies, Anti-Nuclear
Antibodies (ANAs), is among the eleven criteria used to diagnose SLE, however it is not specific
to SLE, so it cannot considered conclusive evidence of SLE.20 ANA is a junk drawer term used
to describe internal components of the cell, and it is not an entirely accurate term since it would
seem to imply that it refers only to components contained within the nucleus.20 The term also
includes other components of the cell such as the mitotic spindle apparatus and cytoplasmic
organelles.20 Typically these components are contained within the cell and would not present any
problems even in the presence of ANAs, but in some cases, such as after apoptosis, these
components can be found outside of the cell, exposing them to ANAs if present.20 The nature of
how components normally contained within the cell become exposed to autoantibodies, eludes to
the greater role that apoptosis plays in the disease process of SLE.20 Double stranded DNA is
another molecule that patients with SLE have been shown to develop antibodies against, with 6090% of individuals with SLE presenting anti-dsDNA antibodies.20 The immune system becomes
exposed to dsDNA in the form of histones, and anti-dsDNA can be specific to different
structures of DNA including the elongated nucleosome linker B-DNA (double-helix, right
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handed turn), phosphodeoxiribose backbones, higher-order bent DNA structure, Z-DNA, and
cruciform DNA structures (left handed turn).20 The presence of anti-dsDNA is also commonly
associated with lupus nephritis (LN) and the renal complications that occur with SLE.20 Similar
to anti-dsDNA antibodies, but not used as a diagnostic marker for SLE, many individuals with
SLE also produce anti-nucleosome antibodies.20 The nucleosome is the larger structure within
which DNA is contained, and the presence of anti-nucleosome antibodies is an even more
consistent indicator SLE than anti-dsDNA, with many of its implications being the same.20
Another group of antigens which SLE patients often produce antibodies against are Sm antigens,
which are named after the patient, Stephanie Smith, in whom these antibodies were first
discovered.20 There are seven core proteins (B, D1, D2, D3, E, F, G) which form a ring for small
nuclear ribonucleoproteins (snRNP), and it is these proteins against which anti-Sm antibodies are
formed.20 In addition to anti-Sm antibodies, individuals with SLE may also form antibodies
against other snRNP including anti-RNP, anti-Ro/SSA and anti-La/SSB antibodies, however
these antibodies are less common than anti-Sm and are not used as a diagnostic marker for
SLE.20 The final type of autoantibody that is used as a diagnostic marker for SLE is antiphospholipid (aPL).20 While found in 30-40% of SLE patients, aPLs are found in other
autoimmune diseases, infections, drug induced disorders, and some healthy controls, which
renders them an ineffective indicator of SLE without the presence of other autoantibodies which
are more specific to SLE.20 The presence of aPLs can often lead to the development of
antiphospholipid syndrome, which is a disorder not specific to SLE that is characterized by
recurrent arterial or venous thrombosis, pregnancy-related problems, thrombocytopenia,
hemolytic anemia, and persistent elevated levels of aPLs.20 Many other autoantibodies have been
discovered in association with SLE including anti-C1q antibodies, anti-ribosomal P (anti-P)

12
antibodies, anti-NMDAR antibodies, anti-annexin antibodies and others which are being newly
identified.20 However, these are not common enough to be used as a diagnostic criteria for SLE
and their role in disease progression is still largely unknown.20 The great diversity of
autoantibodies produced by individuals with SLE points to the larger problem of lack of selftolerance in conjunction with an increased presence of internal cell components which are found
outside of the cell as a result of apoptosis. When these two elements are viewed simultaneously,
the underlying pathogenesis of SLE begins to take shape.

Apoptosis
When considering the prevalence of autoantibodies, it must also be taken into
consideration if there is a process that contributes to the presence and pathogenicity of these
autoantibodies. The role of apoptosis in patients with SLE has become increasingly implicated as
a major contributor to the disease pathogenesis, and can be directly linked to the problematic
nature of autoantibodies.15 Apoptosis is the process by which cells undergo programmed selfdestruction.21 This is an important homeostatic function of the body that counters the process of
mitosis, controlling the number of cells present in the body.21 In healthy individuals, this process
occurs regularly without an inflammatory effect, however in individuals with SLE, the
breakdown of this process can lead to the extracellular exposure of intracellular components, and
can lead to the production of autoantibodies.22 Cells undergoing apoptosis begin the process by
condensing the chromatin present in the nucleus and exhibiting an overall cell shrinkage (Figure
6).21,23 It is the process of cell shrinkage that is the distinguishing marker of apoptosis and what
differentiates it from necrosis which is the alternative form of cell death.21 Necrosis is an
uncontrolled process by which cells die from external stressors or cell swelling and subsequent
rupture.21 Conversely, apoptosis is a highly controlled process with a vast array of genetic
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regulators, and it is the malfunction of
these regulators that is believed to be a
contributing factor to the development of
SLE.22 In addition to the failure of typical
regulators of apoptosis, evidence also
suggests that the irregular buildup of
oxidative stressors may induce irregular
apoptosis in individuals with SLE.24
During the normal process of apoptosis,

Figure 6. Stages of apoptosis.23

following cell shrinkage, the cell
initiates a process call plasma membrane blebbing, where the reduced cell divides into smaller
fragments which maintain the containment of intracellular components within the plasma
membrane.21 These smaller packages of the fragmented cell express signals on their surface that
act as signals for destruction by phagocytes such as macrophages, parenchymal cells, or
neoplastic cells.21,22 The molecules expressed on the cell surface include phosphatidylserine
(PS), phosphatidylcholine (PC), and phosphatidylethanolamine (PE), and in addition to these
signals on the cell surface, the release of adenosine triphosphate (ATP) and uridine triphosphate
(UTP) also recruits phagocytes to engulf the apoptotic bodies.22 In conjunction with abnormal
rates of apoptosis, there also appears to be a decreased ability to clear apoptotic bodies in
patients with SLE.22 If the apoptotic bodies are not properly cleared, the plasma membrane
begins to breakdown, leading to what is called secondary necrosis.22 Secondary necrosis results
in the internal cell components being released into the extracellular space.22
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Figure 7. Programmed cell death pathways.22
In addition to typical routes of apoptosis being dysregulated and dysfunctional, there are
also atypical routes of apoptosis that have been implicated in the pathogenesis of SLE (Figure
7).22 The most likely contributor to SLE is a specific type of cell death that occurs in neutrophils
called NETosis.22 This form of cell death results in the formation of a neutrophil extracellular
trap (NET), which is composed of decondensed chromatin decorated with intracellular
components, including neutrophil elastase (NE), myeloperoxidase (MPO), high mobility group
protein B1 (HMGB1), proteinase 3 (PR3), and LL-37.22 Specifically the presence of
decondensed chromatin seems to implicate NETosis as a likely contributor to the formation of
SLE, since the presence of anti-dsDNA is among the main indicators of SLE.22 Patients with
SLE have also been shown to have higher levels of a specific type of neutrophil called lowdensity granulocytes (LDGs) which release higher amounts of inflammatory signals and show an
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increased susceptibility to spontaneously undergo NETosis.22 Compounding the effects of the
increased activity of NETosis, SLE patients show a decreased ability to degrade NETs compared
to healthy individuals and the increased presence of autoantibodies in SLE patients also hinders
the breakdown of NETs.22 Along with NETosis, other atypical routes of cell death including
pyroptosis and necroptosis have been shown to contribute to disease manifestation of SLE, with
both leading to intracellular components being exposed to the extracellular space.22 The evidence
points to a consistent failure in individuals with SLE to properly regulate cell death and clear cell
debris following cell death, which then correlates with the increased presence of autoantibodies
produced in response to the excess of intracellular materials present in the extracellular space.
These factors combine to culminate in the excessive inflammatory response produced by the
immune system, which is responsible for the many clinical disease manifestations of SLE.

Inflammation
At the junction of the previously described factors of dysregulated apoptosis and the
subsequent prevalence of autoantibodies, the disease pathology of SLE begins to take shape. It is
the nature of the class of diseases to which SLE belongs, autoimmune diseases, and its systemic
nature that point to how these factors combine to produce widespread and constant pain for
individuals with SLE. Autoimmune diseases are characterized by one’s own immune system
using mechanisms designed to combat foreign pathogens to attack self. The production of
antibodies that bind to self-molecules leads to widespread chronic inflammation, which is
initiated by antibodies that activate the complement system.
The complement system is the primary noncellular component of the body’s innate
immune system, which is the nonspecific branch of the immune system.25 The immune system is
generally divided into the adaptive and innate immune systems, which are defined by their
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abilities to either respond to specific pathogens or respond nonspecifically to invaders.25
However, breaking up the immune system into these categories ignores the interconnectivity of
the immune system and the ways in which the adaptive and innate systems work together to
achieve the common goal of defending the body against attack.25 It is at one of these junctions
that the complement system combines the functions of the adaptive and innate immune systems
to wreak havoc on the body in the disease process of SLE. The complement system is comprised
of over 30 proteins which circulate in the blood and respond in specific ways to chemical
signals.25 There are three different pathways within which the complement system operates: the
classical pathway, the alternative pathway, and the lectin pathway (Figure 8).25 Each pathway is

Figure 8. The complement pathways.25
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activated by different chemical signals and each results in a different cascade reactions, but all
pathways converge into a set of responses that protect the body by way of inflammation, cell
lysis, or osponization.25 It is the classical pathway that concerns SLE, because the it is activated
by the binding of the first protein in the classical pathway, C1q, to the Fc region of an antibody.25
Following the binding of C1q to the Fc region, the C1 complex forms via the addition of C1r and
C1s serine proteases to C1q.25 This complex then cleaves C4 into a small fragment, C4a, and a
large fragment, C4b, along with C2 into a large fragment, C2a, and a small fragment, C2b.25 The
combination of C4b and C2a on the surface of the antigen results in the formation of a new
complex called C3 convertase, which then has the ability cleave C3 into C3a, which is an
anaphylatoxin, and C3b, which is an opsonin.25 After C3b is cleaved, it then combines with the
C3 convertase to form C5 convertase, which then generates C5a and C5b, which both act as
anaphylatoxins.25 The formation of C3 and C5 convertase is the point at which all three pathways
converge.25 These pathways produce three main responses (MAC assembly,
anaphylatoxin/inflammatory response, and opsonization), of which the inflammatory response is
central to the development of SLE.25
The result of the immune response to the autoantibodies generated by individuals with
SLE is widespread chronic inflammation.26 The disease pathology generated by chronic
inflammation results from the effects of the body being in a long-term state intended to be an
acute response.26 The response generated by proinflammatory signals includes the expansion of
blood vessels (vasodilation), increase in blood flow, capillary permeability, and migration of
neutrophils into the infected tissue through the capillary wall (diapedesis).26 Typically in acute
inflammatory responses, the primary white blood cells recruited via chemotaxis are neutrophils,
however during chronic inflammation, the composition of recruited cells changes to mainly
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macrophages and lymphocytes because neutrophils have a short life cycle.26 The symptoms often
associated with this response are redness and swelling, since the recruitment of white blood cells
requires blood vessels to become more permeable, which results in fluid accumulation at the site
of the antigen.26 The long term recruitment of macrophages, lymphocytes, and plasma cells
results in tissue damage due to the mechanisms these cells use to attack antigens, and the
damaged tissue is then repaired using fibrous connective tissue which fails to perform the
function of the original tissue.26 The presence of swelling causes pain in affected areas due to the
pressure placed on surrounding tissues, and the replacement of the original tissues with fibrous
tissues results in organs failing to preform efficiently or at all.26 This process of excessive
prolonged inflammation broadly explains the variety of symptoms experienced by patients with
SLE.

Genetic & Environmental Factors
While the exact cause of SLE remains unknown, there are a number of contributing
factors that have been linked to the pathogenesis of SLE.2 There appears to be no single cause for
the development of SLE, but rather there appears to be a combination of genetic and
environmental factors.2 If the cause were strictly genetic, the expectation would be that in cases
where monozygotic twins carry the genetic traits to develop lupus that both would develop
lupus.27 However, this is not the case; both twins develop SLE only 24-35% of the time and the
rest result in only one of the monozygotic twins developing SLE.27 That being said, there is
certainly a genetic component to the development of SLE, which can also be demonstrated by
monozygotic twins.28 Studies have shown that monozygotic twins are ten times more likely to
both develop SLE than dizygotic twins, and that first-degree relatives are twenty times more
likely to develop SLE than the general population.28 This indicates that in addition to a genetic
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component that predisposes individuals to the development of SLE, there must also be an
environmental component that triggers the pathogenesis.
Significant amounts of research have been done attempting to discover genetic factors
that might predispose someone to SLE, including many genome wide association studies
(GWAS).28 There have been over 40 different genes that have been linked to the formation of
SLE with many being complex and polygenic and some being monogenic in nature.28 One major
region of the genome that is believed to play a role in disease pathogenesis is the classical human
leukocyte antigen (HLA) complex, which is responsible for a wide range of genes that function
in the immune system.28 This region serves as the encoding region for the major
histocompatibility complex (MHC), which enables the immune system to recognize self from
non-self.28 Some of the most prime examples of a polygenic source of disease development are
the genes that regulate interferons (INFs), interferon regulating factors (IRFs).28 Many studies
have connected the dysregulation of interferons to the development of SLE, with some studies
even showing that SLE can be induced by increasing levels of INF-.28 Other polygenic sources
include genes that code for STAT4, IFIH1 and osteopontin (OPN).28 Conversely, there have also
been monogenic causes linked to SLE such as complement component C1q deficiency, threeprime repair exonuclease 1 (TREX1) or deoxyribonuclease 1-like 3 (DNASE1L3).29 These
examples only scratch the surface of the wide range of genes that have been linked to the
development of SLE, and genes alone do not tell the whole story, as a genetic predisposition
does not guarantee that an individual will develop SLE.
In addition to a genetic predisposition, certain environmental factors must also contribute
to the development of SLE. It is these environmental factors that are the most difficult to study in
connection to the development of SLE. While some environmental factors, such as ultraviolet
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radiation (UVR) exposure, can be easily linked to flare-ups and disease progression, it is very
difficult to connect any specific environmental factors to the onset of the disease.30 While there is
a very strong connection between UVR exposure and the development of rashes, which are
among the hallmark indicators of lupus, it is difficult to say if it is the UVR exposure led to the
onset of the disease or merely aggravated it.30 Some studies haves suggested links to various
other environmental factors including silica, current cigarette smoking, oral contraceptives,
postmenopausal hormone therapy, air pollution, solvents, pesticides and heavy metals.8
Environmental factors such as these have been linked to many other diseases, namely cancer, and
all prove very difficult to study in relation to the beginning of the disease.8 Among the many
environmental factors linked to the development of SLE are viruses, which have been implicated
in other disease processes, having even been definitively tied to the development of certain
cancers.31 For the purpose of this review viruses will be the primary environmental factor that is
investigated in connection with the onset of SLE.
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Viruses and Autoimmunity
The pathogenesis of systemic lupus erythematosus (SLE) has proven incredibly difficult
to elucidate, and upon examination of the pathophysiology of the disease, there appears to be
numerous factors that contribute to the onset of SLE. Only on rare occasions such as a C1q
deficiency, does there appear to be a single aberration that leads to the development of the
disease.29 It appears that the combination of genetic factors and environmental factors leads to
the development of SLE, and the particular environmental factor that appears to have the most
evidence to connect it to the onset of SLE is viruses.32 This hypothesis is based on the known
mechanisms involved in viral infection and the immune response to a viral infection. This
knowledge has led to the development of potential mechanisms of viral activation of
autoimmunity, some of which have been supported in murine models.33 When the mechanisms
are viewed in conjunction with the known factors that contribute to the onset of SLE, the case for
the viral onset of SLE becomes very compelling; with the last piece of the puzzle being the
ability to test this hypothesis, which will be discussed in the following chapter.

Viruses
A brief introduction to viruses is necessary before detailing how the immune system
attacks viruses. A virus is an obligatory parasite, which means that it requires a host to survive.34
While viruses exhibit many of the characteristics of life, viruses do not qualify as living
organisms.34 Often times words used to describe viruses would seem to imply that they are alive,
however they lack the ability to reproduce on their own, which is one of the criteria for life.34
Viruses are small packages of information in the form of DNA or RNA that are surrounded by a
protein coat or capsid, sometimes containing other molecular machinery such as enzymes.34 By
themselves, viruses are not capable of reproduction, but they can hijack the machinery of other
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living organism to replicate themselves.34 In this way, viruses appear to exhibit all of the
characteristics of life, however they fall short only because they lack the ability to replicate
without a host.
Viruses are highly specific to the host that they infect.34 Viruses infect a host cell by
binding to receptors on the surface of a cell and inserting their genetic material into the host
cell.34 This can be accomplished by either fusing the viral capsid with the host membrane or
directly inserting the genetic material into the host cell while leaving the capsid outside.34 Since
the virus can only bind to specific proteins on the cell surface, typically a virus can only infect a
small range of cells within a given species.34 Occasionally a mutation in the genetic information
contained within the virus can cause a significant enough modification that a virus can jump
species, and these mutations typically lead to some of the more deadly viral infections that
humans experience such as the human immunodeficiency virus (HIV), which was originally
found in apes and monkeys.34 The survival of a virus is dependent on its ability to infect a host
and subsequently be transmitted to a new host.34 If a virus is too efficient at infecting a host and
taking over the host, the host will not live long
enough to transmit the virus, and if the virus is
not effective enough at infecting the host it will
fail to be passed on.34
The “life” cycle of a virus consists of
entering a host cell and integrating it’s genetic
material with the that of the host.34 The virus
will then enter one of two cycles: lytic or
lysogenic (Figrue 9).34 The lytic cycle consists

Figure 9. Viral lytic and lysogenic cycles.34
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of allowing the host cell to duplicate the virus using its cellular machinery until there are so
many viral particles in the cell that the cell bursts or lysis, allowing the replicated viruses to
infect other cells.34 The lysogenic cycle allows the cell to continue replicating itself with the viral
genetic material integrated into the host’s genetic material.34 This perpetuates the viral genetic
material in subsequent generations of the cell, and eventually the virus will reenter the lytic cycle
and complete the steps of the lytic cycle.34 It is the lytic cycle that is deadly for the host, since the
completion of this cycle results in the death of the cell, and the viral replication increases at an
exponential rate.34 Unless the host can stop the spread of the virus, the virus will eventually kill
the host by destroying entire cell populations.34

Human Immune Response to Viruses
The human body is equipped to handle the invasion of viruses with the immune system’s
various cell types and methods of protecting the host from invasion.33 The innate immune system
contains many elements that respond to viral particles, slowing down the rate of infection, and
the adaptive immune system is ultimately able to develop a unique response to specific viruses
that in many cases completely eliminate the virus from the body.33 The innate immune system,
which includes the complement system described previously, is the body’s first line of defense
against viral invasion.33 It is not capable of responding to specific viruses, but contains elements
that can react with various nonspecific elements pertaining to viruses.33 Some of the primary
cells that function as a part of the innate branch of the immune system are natural killer (NK)
cells, natural killer T (NKT) cells, neutrophils, macrophages and dendritic cells (DC).33
Macrophages and DC are among a class of cells called antigen presenting cells (APC), which can
engulf viral particles and present them to cells in the adaptive branch of the immune system.33
These cells along with NK cells have receptors on their cell surface called Toll-like receptors
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(TLR), which can bind to nonspecific elements of viruses such as dsDNA, ssRNA and dsRNA.33
The TLR initiate the release of molecules called interferons (IFN), which activate NK cells and
induce an antiviral state in cells which inhibits protein synthesis rendering the virus incapable of
replicating.33 Activated NK cells can induce cell death in infected cells and release inflammatory
cytokines.33 NK cells can recognize an infected cell by the amount of MHC expressed on a cell
surface.33 Infected cells express lower amounts of MHC on their cell surface, enabling NK cells
to recognize infected cells without needing to be able to respond to the specific virus.33 In
addition to the cells that contribute to the innate response, molecules such as the complement
system described previously, cytokines, TNF-, IFN-, IL-12, IL-6, and chemokines such as
MIP-1 play a role in the innate response.33 Despite the best efforts of the innate immune
system, viruses are only slowed down by the innate branch, and it is the adaptive immune system
that possesses the ability to respond specifically to viruses and completely eliminate them.
Central to the adaptive immune system’s ability to recognize specific viruses are the
specific receptors present on the surface of cells that function within the adaptive immune
system.35 The adaptive immune system is composed of two main cell types: B lymphocytes (B
cells) and T lymphocytes (T cells).33 B cells and T cells express highly specific receptors on their
cells surface called B cell receptors (BCR) and
T cell receptors (TCR) respectively (Figure
10).35 Each immature B cell or T cell has one
unique type of BCR or TCR expressed on its
cell surface and throughout the body there are
as many as 106-107 possible receptor
variations.35 Each of these receptors has the

Figure 10. B cell with BCR or
immunoglobulin (Ig), and T cell with TCR.35
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potential to respond to a specific antigen, and upon encountering the right antigen with proper
activation, the activated cell will clonally reproduce itself and proliferate throughout the body.35
Equally important in the recognition of viral particles are the MHC receptors.36,37 There are two
classes of MHC receptors: MHC I and MHC II.35 MHC receptors combine segments of the virus
with the receptor to be presented on the surface of the cell.36 Infected cells present MHC I
molecules on their surface, and APC are capable of presenting antigens on either class I or II
MHC molecules.36 The MHC then corresponds with the BCR or TCR of the specific B cell or T
cell that is primed to respond to a specific virus or pathogen.36,37 These highly specific receptors
allow for APC to activate an appropriate T cell response, and for the subsequent T cell response
to attack appropriate cells and activate additional help.33
T cells are primarily responsible for eradicating viruses from the body by directly
attacking infected cells and activating B cells.36 T cells are categorized based on the receptors
expressed on their cell surface and their corresponding function.36 The two major classes of T
cells are CD4 and CD8 T cells, which both express different MHC receptors on their cells
surface, with CD4 T cells expressing MHC class II and CD8 T cells expressing MHC class I.36
The MHC class dictates the immune cells with which the T cells can interact.36 B cells only
express MHC II and can only interact with CD4 T cells, while APC contain both MHC I and II
enabling them to interact with both CD4 and CD8 T cells.33 CD8 cells are also called cytotoxic T
(Tc) cells, which eludes to their role in killing infected cells.36 Upon activation by a APC, Tc
cells proliferate and the TCR on the Tc cell binds to the MHC 1 receptor on infected cells.36
Upon binding with an infected cell, Tc cells release cytotoxic granules that induce apoptosis or
cytokines that have an antiviral effect and can rid the cell of viral particles without killing it.33
CD4 T cells can be further broken up into T helper cells (Th) and T regulatory (Treg) cells, with
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the Th cells playing the largest role in viral defense.36 Th cells are necessary for the activation of
B cells.37
The role of B cells has been previously eluded to in the discussion of antibodies and their
role in the disease pathogenesis of lupus. Specifically, in the case of viral infection, B cells
produce antibodies that bind to specific regions on the virus called epitopes.38 The binding of
antibodies to the viral particles both inhibits them from entering the cell and marks them for
phagocytosis.38 The activation of B cells to produce these highly specific antibodies occurs after
the B cell has both encountered the pathogen and been activated by a Th cell.37 As mentioned
previously, B cells present a specific BCR on their surface which is in fact an IgM or an IgD
molecule which were previously described in the discussion of antibodies.35 Each immature B
cell presents as many as 100,000 of the same Ig on its surface.35 When a virus binds to an
immature B cell BCR, the B cell takes in the virus and integrates parts of it to the MHC, and is
then activated when the TCR of a Th cell binds to the MHC.37 After the B cell is activated, a
series of changes allow the B cell to class switch to produce IgG molecules, and the B cell
further differentiates into either memory cells or plasma cells.37 Plasma cells are responsible for
secreting soluble antibodies into the bloodstream and these cells are proliferated throughout the
body following B cell activation and differentiation.37 The memory cells continue to survive
even after the virus has been eradicated allowing the body to retain the ability to mount a defense
if ever presented with the same virus.37 Additionally some of the plasma cells retreat to the bone
marrow where they continue to secrete low levels of antibodies.37 The memory of the adaptive
immune system is not limited to the B cells, with some T cells being maintained by IL-7 and IL15 which regulate survival and proliferation respectively.33
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It is the normal response to viruses that informs the hypothetical connection between
viruses and the onset of autoimmune disease. While the immune system is typically incredibly
effective at attacking and eliminating viruses, the mechanisms used to do this must be tightly
regulated.33 Furthermore, while the immune system is capable of completely eliminating most
viruses, there are some viruses that can avoid complete eradication which can lead to the
perpetual activation of the immune system.33 So while in most cases the immune system does its
job and does it well, there are circumstances that open the door to malfunctions which have the
potential to trigger an already genetically susceptible individual.

Molecular Mimicry
There are few main mechanisms that have been proposed to explain how a viral infection
can lead to the development of an autoimmune disease.32 One of which is called molecular
mimicry, which describes a molecular form of survival tactic that has been applied at larger
scales throughout all forms of life.39 Various organism have evolved to share similarities with
their environment that allow them to evade detection from other organism that might seek to
destroy them.39 Infections microorganism are no exception, with many exhibiting characteristics
similar to the host and allowing these microorganisms to evade detection by the host’s immune
system.39 In order for a virus or another pathogen to be an effective infectious agent, it must be
able to at some level avoid the host immune response; otherwise it would quickly be detected
and eradicated.39 The term “molecular mimicry” was first coined by Damian in 1964 to describe
the similarities between surface markers on antigens and host cells that allowed the antigen to
avoid detection.40 Two years later, Zabriskie and Freimer demonstrated that membrane structures
on group A streptococcus shared commonalities with membrane structures found on human
muscle tissue.40,41
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The proposed mechanism by which autoimmune diseases develop via molecular mimicry
involves the activation of autoreactive immune cells by the pathogen bearing resemblance to the
host cells.32 In a healthy immune system, T cells are rigorously screened for self-tolerance in the
thymus, and any self-reactive cells are terminated.40 However, it is possible that these selfreactive T cells may avoid detection in a few different ways.40 The simplest explanation is that a
self-reactive T cell may simply have a TCR that is reactive to both an antigen and self, and
simply fail to be detected during the screening process.40 This type of failure may be due to
genetic abnormalities.40 Another way an autoreactive T cell could avoid detection in the thymus
is the presence of two TCRs.40 As many as 30% of T cells in the body have two TCRs with the
potential for one of the TCRs to be self-reactive yet still avoid detection.40 Lastly, it is possible
that specific combinations the  and  chains may lead to a “chimera” combination that is
capable of recognizing self, but somehow avoids detection in the thymus.40 The presence of these
autoreactive T cells is the basis of molecular mimicry leading to the development of autoimmune
diseases such as SLE.40 If these autoreactive T cells are present in the body, they may remain
inactivated throughout the entirety of a person’s life; however, if exposed to a pathogen that
bears an epitope similar to the self-antigen, this can lead to the activation and proliferation of a
population of T cells that are autoreactive and later the activation of B cells that release
autoantibodies.40
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Figure 11. Criteria for identifying molecular mimicry.40
Three broad categories have been developed to describe the types of molecular mimicry
that can occur.39 The first category describes peptide chains that are identical in both the host and
the pathogen.39 The second type of molecular mimicry is when the epitope on the antigen is
structurally similar to an epitope on a host cell, allowing for cross reactivity by the host immune
system.39 Finally, there are occasions where the completely dissimilar structures can be
recognized by the same antibody, causing a rare type of cross reactivity that is not caused by
similarity in structures.39 These types of molecular mimicry have been observed in various
experiments leading to the development criteria for identifying molecular mimicry.40 There are
four major criteria (Figure 11) with the first being that host and microorganism or environmental
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agent share a similar epitope.40 The second criteria require that patients with autoimmune
diseases have detectable antibodies or T-cells that cross react with both epitopes.40 For the third
criteria an epidemiological link must be established between contact with the microorganism or
environmental agent.40 Finally, the fourth criteria mandates that the autoimmunity must be
reproducible in an animal models exposing the subjects to the same microorganism or
environmental agent possessing the epitope in question.40 These criteria have proven difficult to
demonstrate in human models, and these shortcomings have led to doubt that molecular mimicry
is responsible for the onset of autoimmune diseases in humans.40
Despite the lack of evidence in human models to definitively link molecular mimicry to
the development of autoimmune diseases, there have been several examples of animal models
that have demonstrated this connection.40 In the early 1980’s work done by Fujinami et al.
demonstrated that mice developed antibodies to measles virus and herpes simplex virus (HSV)
that cross reacted with human cells, and later work by this group demonstrated that myelin basic
protein (MBP) shared homology with the hepatitis B virus polymerase (HBVP) and after
exposing rabbits to these moieties, they developed encephalomyelitis.40 In addition to work done
with animal models demonstrating the link between molecular mimicry and autoimmune
diseases, numerous studies have been done providing evidence for a potential link between
viruses and the development of autoimmune diseases in humans via molecular mimicry. Some
examples include T cells showing reactivity to both MBP and EBV nuclear antigen 1 (EBVNA1)
in patients with MS, similarities between epitopes of pancreatic β cells and viral components
along with a correlation in the rise of cases of type I diabetes and enterovirus epidemics, and
cross reactivity between EBVNA1 and Sm proteins in patients with SLE.40 The difficulty with
each of these examples is that none of them provide a definitive connection between the virus
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and the autoimmune disease. Each provides circumstantial evidence and a plausible mechanism
in molecular mimicry, but there are so many factors that contribute to the development of
autoimmune diseases that current methods fall short of linking the two.

Bystander Activation
Another potential mechanism linking the development of autoimmune diseases to viral
infection is called bystander activation.32 Among the three potential mechanisms linking AD
development to viruses, this mechanism has the least amount of evidence both supporting it and
potentially linking it to the development of SLE.42 In fact, evidence suggest that this mechanism
could potentially have a protective effect in SLE by activating T cells with an
immunosuppressive effect.42 Despite the lack of evidence, there still remains theoretical potential
due to the possible activation of autoreactive T cells via this mechanism. Each mechanism is
ultimately reliant on the activation of autoreactive T cells that are already present in a susceptible
individual, with each describing a mechanism by which a viral infection could lead to this
activation.
The mechanism by which bystander activation works can be described in two different
ways, with one lending similarity to epitope spreading, which is the final mechanism that will be
discussed. The primary definition of bystander activation is the activation of bystander T cells
that does not involve the TCR.42 This mechanism proposes that during a viral infection either
memory T cells or naïve T cells can be activated by soluble mediators released by T cells
actively fighting the infection.42 It has been demonstrated that CD8 T cells can be activated by
soluble mediators such as IL-12, IL-15, IL-18, and type I INFs.43 It is proposed that during a
viral infection, the T cells fighting the infection can activate T cells which are not specific to
virus by bystander activation through the release of these soluble mediators.42 These T cells
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activated through bystander activation have been shown to contribute to inflammation though the
production of inflammatory cytokines such as INF-.43 Additionally, this mechanism has been
shown to work similarly in memory-like CD4 T cells in response to the release of IL-1β and IL23.44 In a study on the role of bystander activation in autoimmune encephalomyelitis these CD4
T cells were shown to contribute to inflammation via the production of IL-17A and IFN-γ.44 The
alternate way in which bystander activation is described overlaps with the description of epitope
spreading, which needs to be described separately.

Epitope Spreading
Out of the three mechanisms, epitope spreading aligns the closest to the pathogenesis of
SLE. The known factors that contribute to the pathogenesis of SLE are impaired apoptotic
clearance and self-reactive lymphocytes which lead to the development of autoantibodies and
widespread inflammation.29 The basis of epitope spreading is that a prolonged viral invasion
leads to the exposure of cellular components that activate autoreactive lymphocytes, and
subsequently lead to the spreading of lymphocytes that are reactive to self-epitopes.45 There are
two routes that can lead to the recognition of self-epitopes by lymphocytes during a viral
infection, and both are initiated by the mechanisms that immune system normally uses to fight a
viral infection.45
The first route of epitope spreading begins with the influx of lymphocytes to an infected
area, which in a normal immune response involves Tc cells inducing apoptosis in infected cells.45
The influx of lymphocytes in addition to the pervasive cell death can lead to the introduction of
autoreactive lymphocytes to intracellular components.45 Since the normal immune response leads
to the recruitment of lymphocytes, this increases the likelihood that an autoreactive lymphocyte
will be recruited to an area of viral infiltration. The method by which Tc cells eradicate the virus
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can then lead to the exposure of epitopes that would not normally be found in such large
quantities.45 These two factors can lead to the right sequence of events for autoreactive
lymphocytes to proliferate following the exposure to epitopes that were present in the wake of an
immune response to a viral infection.45
The second route by which epitope
spreading can lead to the development of
autoimmunity is mediated by APCs (Figure
12).45 This route closely resembles bystander
activation, and some descriptions of bystander
activation will match this description of
epitope spreading.32,45,46 The main difference
between the typical definition of epitope
spreading and the similar definition of

Figure 12. Bystander activation via APC.45

bystander activation is epitope spreading is generally connected to a chronic viral infection, and
bystander activation is generally associated with an intense acute viral infection.32,45,46 The
mechanism ends up being incredibly similar and the name becomes inconsequential. The
difference between the second route of epitope spreading and the first is the presentation of the
epitopes by APCs as opposed to the lymphocytes being directly exposed to the epitope.45 In this
route, the persistent availability of intracellular components leads to these components being
taken up by APCs and then the epitopes of these components are integrated into the MHC of the
APC.45 The APC then presents these epitopes to self-reactive lymphocytes leading to the
proliferation of these lymphocytes and the eventual production of autoantibodies, which is the
major contributor to the pathophysiology of SLE.20,45 This particular route of epitope spreading
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has the potential to be even more harmful than the first. The uptake of self-molecules by APCs
and subsequent presentation to lymphocytes can lead to the recognition of multiple self-epitopes
as a result of the process by which epitopes are integrated with MHC.45 When APCs engulf a
self-molecule, they can integrate more than one epitope from that molecule to the MHC.45 This
creates the potential for epitopes that may be shared by more than one self-molecule to be
recognized, leading to the recognition of multiple self-molecules by autoreactive lymphocytes.45
The uptake of one self-molecule by an APC can then lead to the recognition of another and
potentially then leading to the production of a variety of autoantibodies, a hallmark of SLE.45
As with the other proposed mechanisms of viral induction of autoimmunity, the evidence
supporting this mechanism is primarily in animal models. One popular example is the persistent
infection of Theiler’s virus in mice, which leads to the development of an experimental
autoimmune disease, experimental allergic encephalomyelitis (EAE).47 A more recent example
of experimental evidence for epitope spreading is an experiment on mice that showed epitope
spreading in experimental autoimmune uveoretinitis (EAU).48 The obvious limitations with both
of these examples is the experimental nature of these autoimmune disease and their restriction to
mice. However, studies have been done linking multiple viruses and epitope spreading in
humans to SLE, which provides evidence that this mechanism could explain the pathogenesis of
SLE.49–51

Connecting Viruses to Autoimmune Diseases
Each of these three mechanisms provide plausibility to the hypothesis that viral infections
could play a pivotal role in the development of an autoimmune disease such as SLE. The
difficulty in proving this connection has always been the limitations in experimental design. In
order to provide more conclusive evidence regarding this connection a study would have to
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figure out both the identity of the virus causing the autoimmune disease and what autoimmune
disease(s) that virus causes. A study of this size and scope has not previously been possible with
available technologies as there are over 200 different viruses that commonly infect humans and
there are almost 100 different autoimmune disease.52,53 Even focusing on just one autoimmune
immune disease requires selecting only one or a few viruses to investigate, which amounts to a
shot in the dark. Any evidence that is acquired requires enormous amounts of additional data to
eliminate all other explanations for the results obtained from such a study. A comprehensive
study would require the ability to test people for every virus with which humans are commonly
infected and a longitudinal analysis of the autoimmune diseases developed after viral exposure.
VirScan has been recently developed and could accomplish this goal.
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VirScan
In science, every technology is built on the foundation of previously discovered
technologies. Observations that had been made in the past can be taken and applied to propose
new hypotheses, which lead to new discoveries. Without the former, the latter would not exist.
The technology used to test the hypothesis of my paper is no different. To understand the
significance of this technology, it must be broken down into its essential components. After
understanding how these components work, the application becomes both easier to understand
and more obvious. What the technology accomplishes is simple to explain, but how it
accomplishes it and the application of it are less simple. VirScan is a combination of several
different techniques that makes it possible to test a small sample of a person’s blood and
determine what viruses that person has likely been exposed to during their lifetime.54 The central
component that makes this possible is called Phage Immunoprecipitation sequencing (PhIP-seq),
which is in of itself the summation of several different techniques that accomplish a central
goal.54 The supplemental technology that provides the efficiency and financial feasibility of
creating and using a technology like PhIP-seq is owed to the advances in DNA sequencing and
analysis, de novo DNA synthesis technologies, and development of T7 bacteriophage libraries.55

High Throughput DNA Sequencing
The fundamental aspect of identifying viruses is the genetic code. Viruses are coded with
either ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), which dictate what the virus
looks like, what kind of cells it can infect, and virulence. Reading this code is central to
understanding the identity of a virus as well as understanding its components. The genetic code
consists of five nitrogenous bases that each correspond with a letter: adenine (A), guanine (G),
cytosine (C), thymine (T), and uracil (U).56 Theses bases are connected to one another by a sugar
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phosphate backbone.56 The type of sugar that comprises the backbone in conjunction with the
bases that make up the genetic code differentiate the make-up of DNA from RNA.56 DNA uses
thymine instead of uracil and RNA does the opposite, which means that the genetic code for both
is comprised of four-letter units and can be translated from one to the other. When translating
between the two, uracil corresponds with thymine.56 The order in which these bases are arranged
along a DNA or RNA strand determines the various characteristics of the virus. Dr. Fredrick
Sanger earned a Nobel prize in Chemistry in 1980 for developing a method for reading a DNA
sequence.57 His method uses fluorescently labeled 3′-dideoxynucleotides (ddNTPs) to cause
identifiable termination in DNA elongation.57 DNA is normally replicated using DNA
polymerases, which are enzymes that are able to duplicate an entire strand of DNA.56 His method
first uses DNA polymerase to amplify the DNA strand that is being read and once there are
numerous copies, the DNA is allowed to copy with ddNTPs present.57 Whenever a ddNTP is
entered into the growing DNA strand, elongation is terminated.57 This process produces DNA
strands of varying lengths, from which the DNA code can be elucidated.57 While the
development of this technology was groundbreaking, it was also very limited. It cost over a
billion dollars and took almost a decade to sequence a human genome using Sanger’s method.57
The Sanger method would be far too expensive and require too much time to scan libraries of
viral genomes.
VirScan scans libraries of viral genomes to determine an individual’s exposure to
different viruses.54 The technology that makes it possible to read and analyze the number of
DNA sequences used by VirScan is called high throughput sequencing (HTS) and is capable of
sequencing an entire human genome in one or two days for $1,000 or less.57 The process is
several magnitudes cheaper and shorter than Sanger’s initial method, but is built on the same
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principles. The leading company
in HTS, Illimuna, uses a bridging
technique to achieve fast and
inexpensive DNA sequencing
(Figure 13).57 This technique
employs oligonucleotide (oligo)
strands that are anchored to glass
flow cells.57 After splicing the
original DNA sequence into
many smaller sequences, the
smaller sequences are modified
with identifiers and sequences
that complement the oligo
strands in the flow cells.57 Once
attached to the oligo strands, these

Figure 13. Overview of DNA-sequencing using the Illumina
platform.57

DNA segments are replicated using a process called bridge amplification.57 Once the strands
have been replicated hundreds of thousands of times, these strands are read using fluorescently
tagged nucleotide bases.57 The order of the DNA sequence can then be reconstructed by
overlapping sequences and computational analysis of the data collected during the addition of the
fluorescent tags.57 Most of this process is automated and requires very little manual labor.57

De Novo DNA Synthesis
In addition to being able to read the genetic code of viruses, the VirScan technology also
requires the ability to write a synthetic genetic code. The technique for synthetically creating
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oligo strands was developed in the
1950s by Todd, Khorana, and their
colleges.58 At its core, it is a reaction
that forms a phosphodiester bond
between two nucleosides, which in
isolation, is not a difficult reaction to
achieve.58 The difficulty of
synthesizing a DNA strand of a
desired sequence, is controlling the
order in which the nucleosides are
58

Figure 14. Four step synthetic oligo synthesis.58

added. Controlling which
nucleosides are added is achieved in four steps (Figure 14).58 The first step is the attachment of a
dimethoxytrityl (DMT)-protected nucleoside phosphoramidite to a solid support and then
deprotecting it using trichloroacetic acid.58 The second step is to add the desired DMT-protected
nucleoside to the newly unprotected 5′ hydroxyl group, which forms a phosphodiester bond.58
The 5′ hydroxyl group can then be capped by acetylation to prevent degredation.58 Finally, the
phosphite backbone is oxidized via iodine oxidation resulting in a cyanoethyl protected
phosphate backbone.58 The process is started again by removing the DMT, creating a cycle that
can be repeated until the desired sequence has been obtained.58 Once this process has been
completed, the oligo can be removed from the solid support, and the backbone and bases can
have their protecting groups removed.58
It was not until HTS became widely available and paved the way for understanding the
language of DNA, that the technology for writing original DNA became relevant for research
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purposes.58 It is no use writing in a language, if what is being written is unknown. As with initial
methods for DNA sequencing, the originally developed methods for synthesizing oligos were not
efficient enough or accurate enough to be applied on a large scale like what is necessary for
VirScan. Current methods use ink jet microarrays that are capable of applying exact amounts of
reagents to microarrays that ensure the addition of only the desired nucleoside and achieve a high
level of proficiency in carrying out the desired reaction.58 As a result of such proficiencies, entire
viral genomes can be recreated synthetically such as the 1918 Spanish influenza virus.58 This
technology also opens the door to designing viral genomes to carry out specific functions.

T7 Phage Display Systems
Central to the VirScan technology is the development of bacteriophages that can be
modified to display desired surface antigens. In 1985, George Smith discovered that gene III in a
filamentous phage was responsible for encoding a minor coat protein, and this gene could be
modified to express foreign peptide sequences on the virion capsid.59 His work was further
modified using various phages such as f1, fd, T4, M13 and T7.60 Most modern research employs
the M13 and T7 phages, with the T7 phage being the desired option for the VirScan
technology.54,60 The T7 phage system offers several advantages over the M13 system which
directly apply to how it is employed for the VirScan technology.60 M13 phage display systems
take longer to develop and are more limited in the size of display that is inserted.60 The structural
differences between M13 and T7 phages allow the T7 phages to more easily express the desired
peptide sequence on the surface of the phage and allow for easier insertion of the foreign
cDNA.60 Bacteriophage T7 is one of seven different viruses that can infect and replicate within
E. coli, which makes it a particularly easy vector to use because of the relative ease of growing
and maintaining E. coli cultures.60 The structure of the T7 phage includes an outer shell that is
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composed of proteins gp10A and 10B, a tapered internal cylinder composed of proteins gp6, 7,
14, 15 and 16, a connector composted of gp8, a tail composed of proteins gp7, 3, 11 and 12, and
tail fibers composed of gp17 (Figure 15).60 The location that the desired peptide sequences can
be inserted is at the C-terminus of the gp10B capsid protein which is the secondary capsid
protein and is expressed at a 1:9 ratio compared to the primary capsid protein, gp10A.60 This
allows T7 phage libraries to be customized to express numerous foreign surface proteins without
disrupting the functionality of the phage.60

Figure 15. Detailed structure of T7 phage.60

Phage Immunoprecipitation Sequencing (PhIP-seq)
The PhIP-seq technology was developed by researchers at Harvard and was later slightly
modified and then applied to develop the VirScan technology.54,55 At the foundation of this
technology is the biological principle of antibodies and antigens. As described previously, the
body makes specific antibodies that respond to antigens on specific pathogens. It is then possible
to use these antigens to identify what pathogens an individual has been and is currently exposed
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to based on what antibodies are present in the body. The key to using antibodies to identify
specific pathogens is identifying the specific epitope on the antigen to which the antibody
binds.61
The PhIP-Seq technology combines the technologies of de novo DNA synthesis, T7
bacteriophage libraries and HTS to create a system that is capable of identifying an individual’s
exposure to specific pathogens using the antibodies present in the individual’s blood (Figure
16).55 The first step of PhIP-Seq is choosing a pathogen to be identified.55 Then the epitopes to
which antibodies bind have to be identified.55 Once the epitopes have been identified, the
segment of DNA that codes for the peptide sequence of the epitope must be identified.55 After
the epitopes and their corresponding DNA sequences have been identified, the DNA must be
synthesized and then amplified for fusion with a T7 phage vector.55 The T7 phage vector will
then express the epitope on its surface.55 The expression of the epitope in a vehicle other than the
original pathogen is the greatest limiting factor of this technology.55 The T7 phage vector is only
capable of expressing linear epitopes, but there are several other types of epitopes which
antibodies bind to that cannot be expressed on a T7 phage.55 Examples of epitopes that cannot be
expressed using a T7 phage vector are epitopes longer than 90 amino acids, epitopes containing
post translational modifications, epitopes with disulfide bonds, and epitopes that are
discontinuous.55 Although this limitation means that this technology cannot currently be used to
test every known epitope, linear epitopes provide enough material to make this technology useful
and widely applicable.55 Once the T7 phage library has been developed, the phage library is
introduced to a sample containing antibodies which will then bind to any phage vectors
expressing the epitope to which the antibody is specifically adapted. 55 Once the antibodies are
allowed to bind to the phage vectors, magnetic beads coated with A/G proteins that will bind to
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the antibodies are used to precipitate the bound vectors.55 The identity of the bound vectors is
then revealed using HTS.55 The information obtained using HTS can then be used to determine
the specific pathogen from the antibody sample as well as the amount of antibody present in the
sample.55

Figure 16. Overview of the PhIP-seq methodology.55

VirScan Design
The PhIP-Seq technology was modified to specifically identify known human viruses that
a person may have been exposed in their lifetime, and this modification has been developed into
VirScan.54 In the paper outlining VirScan’s proof of concept, researchers at Harvard tested 569
people from four continents, which amounted to the screening of over 108 antibody-peptide
interactions.54 This technology opens the door to study the effects of viruses that cause both
acute and chronic infection, contributing to what is called the human virome.62 The human
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virome describes all the different viruses that exist within a person, including those that infect
human cells causing disease and those infecting microorganisms that live on or in the host.62 The
current ability to test the human virome and understand the effects of a specific virus on the
human body is limited to doctors making educated guesses.63 Current technologies only allow for
one virus to be tested for at a time, which is a long and expensive process that is often not worth
the effort without conclusive evidence and is one of the primary limiting factors to linking a
virus to the onset of SLE.63 While the technologies for testing specific viruses are becoming
more efficient, they are often times not widely available, and are still limited in their ability to
enhance research into the human virome.64 These tests are limited for research purposes because
they only test for one virus at a time and often require an active infection to be successful.64
To construct a test capable of examining an individual’s lifetime viral exposure, the T7
phage library was designed to include epitopes from all available information on viruses known
to infect humans (Figure 17).54,63 To accomplish this task, Xu et al. constructed a library of
oligonucleotide sequences containing 93,904 different sequences, each being 200 nucleotides in
length and coding for proteins with 56-residues and 28-residue overlaps.54 This library was
compiled using information from the UniPort database.54 This compilation of viral data contains

Figure 17. Systematic viral epitope scanning (VirScan).63
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peptides from 206 species of virus and over 1,000 different strains.54 The vast array of viral
epitopes displayed on this T7 phage library provides an unparalleled amount of information
pertaining to an individual’s viral history.54 The difficulty with collecting this much information
is analyzing it and interpreting it in a way that translates to useful information.
The construction of the T7 phage library is the main modification to the PhIP-Seq
technology that differentiates the two. The rest of the procedure follows the PhIP-Seq protocol.
After the phage library is created, the serological sample is added to the display library. The
phage particles that attach to immunoglobulins from the sample are precipitated using magnetic
A/G beads, and HTS is used to analyze the reactive phages. The interpretation of the data
obtained is the other distinguishing factor that separates the VirScan technology from the
standard PhIP-Seq protocol.
The information obtained from a VirScan test must be interpreted after the procedure has
been completed. A large portion of the work done by the research team at Harvard to develop the
VirScan test into an effective diagnostic tool was taking the data obtained from the protocol and
giving the data meaning.54 Xu et al. developed a computational method that translates the data
obtained from HTS into a test that connects the reactive phage particles with a specific virus and
determines if the number of reactive phage particles corresponds with a positive or negative test
for that virus.54 Existing data on population exposure to different viruses was used to assess the
accuracy of the test. Such data can be used to correct and refine the test so that the accuracy and
specificity of the test can be increased.54 For example, 29% of the samples tested positive for
Cowpox virus, but upon further examination, the peptide sequence of the Cowpox virus that was
reactive with antibodies from the samples is highly similar to a peptide sequence found on the
Clumping Factor B protein from Staphylococcus aureus.54 Finding peptide sequences that have
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similar or overlapping sequences with other known antigens is essential to making the test more
specific.54 The researchers also discovered that there were certain peptide sequences that were
commonly recognized by the patient population which could be used to improve the accuracy of
the test.54 For the respiratory syncytial virus (RSV), the original VirScan results were much
lower than expected, which was verified by using a more accurate test that uses antibodies to
detect a single virus called an enzyme-linked immunosorbent assay (ELISA).54 This test showed
that 95% of the patients tested positive for this virus, but VirScan only showed 63% testing
positive for RSV.54 After adapting the protocol for a positive test using information about
commonly recognized sequences, the test results improved to 97% positive.54 This shows that the
VirScan test can be further modified to increase specificity.54
The novelty of this technology has led to limited applications thus far, with only nine
published research articles having cited VirScan as a diagnostic tool used in the research at the
beginning of 2020. The ways in which the VirScan technology has been employed can be
grouped into three broad categories. The first way that VirScan has been used is to measure the
activity of the immune system. One study used VirScan to measure the antibodies present in the
blood of individuals before and after exposure to the measles virus.65 While another study used
VirScan to measure the antibodies present before and at different points after hematopoietic cell
transplantation.66 The last study that used VirScan to measure immune function, used VirScan to
measure the activity of B cells following CD19-directed chimeric antigen receptor T-cell
immunotherapy on B cell malignacies.67 Another study used VirScan to monitor patients
following kidney transplants, and found VirScan to be highly reliable and cost effective method
of monitoring patient post-surgery.68 This specifically shows that VirScan can be employed as a
cost effective screening method for procedures that could be complicated by the presence of
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certain viral infections. The final application of VirScan that has been demonstrated in research
thus far is the implication of a virus in a disease process that could not previously be
conclusively connected to a specific virus. It is especially difficult to link viruses to neurological
disease processes due to the difficulty of testing for viral particles in the cerebrospinal fluid
(CSF).69 In two separate studies, VirScan was used to implicate the enterovirus A71 (EV-A71) as
the cause of pediatric acute flaccid myelitis (AFM).70,71 This application of VirScan is especially
promising due to the difficult nature of implicating viruses in chronic disease processes. VirScan
has the potential to link previously idiopathic disease processes to viral causes due to its ability
to reveal patients’ viral history even without a pervasive infection or high levels of circulating
antibodies. Additionally, VirScan also introduces the ability to screen for a number of viruses
that was previously impossible from a practical perspective. Prior to the development of
VirScan, viruses had to be scanned for individually and the introduction of this technology
introduces the ability to scan for over 200 viruses at once. This enables for a comprehensive
study examining the entire viral exposure of individual in one cost effective test, which could
make possible the investigation of a viral cause to the onset of SLE.
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Conclusion
A comprehensive analysis of the evidence regarding SLE pathogenesis points to a genetic
predisposition to autoimmunity that is potentially triggered by environmental factors. In the same
way that a Rube Goldberg machine has all the pieces in place to set off a complicated series of
events, individuals with a genetic predisposition to SLE appear to have many genetic
components that can result in autoimmunity; however, if the right event does not take place to set
off the series of interconnected pieces, the disease never develops. The difficulty of connecting
any particular environmental factor to the onset of SLE is twofold. The first being that the onset
of SLE is slow and appears to have a preclinical asymptomatic phase, an incomplete onset phase,
and finally a complete onset phase.29 This makes connecting any environmental factors to the
onset of the disease incredibly difficult, because the exposure to the environmental factor could
have occurred long before the manifestation of the disease; this essentially renders it impossible
to connect the two events, as there has been no way to retroactively go back and connect the
dots. Secondly, designing a method of testing environmental factors for their connection to the
onset of the disease has proven to be a difficult undertaking.33 The scale and precision of an
experiment needed to link the two has thus far proven to be impossible to construct, and any
attempts thus far to connect the two have not provided conclusive enough evidence.33 This sets
the stage for the promise of VirScan being employed as a diagnostic tool for such a study.
Past experiments have always been limited to testing for one or a handful of viruses due
to the limitations of existing technologies. This made any correlations inconclusive because other
viruses could not be eliminated, and it also limited the scope of any study attempted, because it
would not be worth investigating in depth due to the fact that the results would be inconclusive at
the end of the study regardless. The development of VirScan eliminates that greatest limiting
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factor by enabling testing for almost every virus that is known to infect humans in one cost
effective test. This then presents the opportunity to increase the scope of a study investigating the
connection between viruses the development of SLE, because the results obtained would provide
incredibly useful and insightful data regarding the correlation between viral exposure and
subsequent autoimmune disease development. In theory, a longitudinal study could definitively
determine the entire viral exposure for a massive population of subjects over a period of time and
follow the development of any autoimmune diseases such as SLE. If a specific virus or family of
viruses prove to be the causative agent for the development of SLE, a vaccine could serve as a
preventative measure that keeps people from developing SLE.
The literature currently available on the pathology and pathogenesis of SLE strongly
suggest that an environmental factor such as a virus could serve as a trigger for SLE in
genetically susceptible individuals. Additionally, available literature on the correlation between
viral exposure and autoimmunity strongly suggests that the mechanisms exist to initiate a
cascade of events that could then lead to the development an autoimmune disease such as SLE.
Finally, there now exists a technology that makes possible an investigation into this theoretical
connection. The literature reviewed for the purpose of this thesis seeks to provide a solid
foundation on which such a study could be reasonably attempted. In conclusion, the evidence
obtained and laid out throughout this paper demonstrates that the research that has been
conducted thus far investigating the pathogenesis of SLE correlates strongly with research that
seeks to specifically connect viruses to the pathogenesis of SLE. Finally, the literature also
shows that a technology now exists that had not previously been available to test this correlation,
which could then be applied to test the hypothesis of a virus being the causative agent in the
onset of SLE.
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With any disease that is idiopathic in nature, it is critical to determine what leads to the
development of the disease and if it can be prevented. Otherwise, as with SLE, the only solution
is to treat symptoms. When diseases are caused by genetics, current technologies fall short of
cures in most cases. However, when caused by an environmental agent, disease prevalence can
more easily be reduced or even prevent. With SLE, evidence strongly points towards an
environmental cause, and available literature provides strong evidence for a correlation between
that the disease pathology of SLE and mechanisms of interaction between viruses and the
immune system. The previous limitations of research investigating this connection can be
overcome using VirScan to test large populations of people for their exposure to viruses known
to infect humans. This then provides the means to supplement available data that points to
viruses being a causative agent in the development of SLE. Ultimately, this then provides a
direct line to answering the question presented in this thesis, “Can viruses cause lupus?” and
answering this question leads could lead to the prevention of SLE.
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